Skip to main content

Remote Job Finders (RJF)

Shionogi makes $2B rare disease play with IntraBio buy

With its acquisition of IntraBio, Shionogi will gain ownership over Aqneursa, which could hit peak global sales of $1 billion across its two indications in Niemann-Pick disease type C and ataxia-telangiectasia, according to Jefferies.

BioSpace 40 Under 40 winners make their mark on biopharma

40 Under 40 honorees’ accomplishments include co-developing the world’s first synthetic biology programming language for mRNA and co-founding and leading a company acquired for $700 million up-front and up to $1.225 billion in total consideration.
Scroll to top